PremiumThe FlyRallybio downgraded to Neutral from Buy at H.C. Wainwright Citizens JMP downgrades Rallybio on RLYB212 discontinuation Rallybio downgraded to Market Perform from Outperform at Citizens JMP PremiumRatingsPromising Developments and Financial Stability Support Buy Rating for Rallybio Rallybio reports Q4 EPS (25c), consensus (30c) Buy Rating for Rallybio: Progress in Key Therapeutics and Promising Catalysts PremiumThe FlyRallybio announces initiation of Phase 2 clinical trial of RLYB212 Rallybio price target lowered to $5 from $6 at H.C. Wainwright Rallybio reports Q3 EPS (26c), consensus (35c) 
